AMO Pharma Unveils Promising Long-Term Safety Data for AMO-02 in Congenital Myotonic Dystrophy Type 1 Treatment AMO Pharma shares encouraging long-term safety results from the REACHCDM-X study of AMO-02 for congenital myotonic dystrophy. FDA meeting planned.

AMO Pharma Unveils Promising Long-Term Safety Data for AMO-02 in Congenital Myotonic Dystrophy Type 1 Treatment #USA #London #Myotonic_Dystrophy #AMO_Pharma #AMO-02

AMO Pharma Unveils Promising Long-Term Safety Results for AMO-02 in Treating Congenital Myotonic Dystrophy Type 1 AMO Pharma shares vital safety data from its REACHCDM-X study on AMO-02, indicating a favorable profile for treating congenital myotonic dystrophy type 1. Insights reveal sustained efficacy and low adverse events.

AMO Pharma Unveils Promising Long-Term Safety Results for AMO-02 in Treating Congenital Myotonic Dystrophy Type 1 #USA #London #Myotonic_Dystrophy #AMO_Pharma #AMO-02

AMO Pharma Partners to Launch Groundbreaking Clinical Trial for ARVC Treatment AMO Pharma enters a license agreement to support the largest clinical trial for arrhythmogenic right ventricular cardiomyopathy (ARVC), crucial for patients with this condition.

AMO Pharma Partners to Launch Groundbreaking Clinical Trial for ARVC Treatment #USA #Hamilton #AMO_Pharma #ARVC #PHRI

AMO Pharma Partners with PHRI and Venca Research to Conduct Groundbreaking ARVC Study AMO Pharma has signed a license agreement with PHRI and Venca Research for a landmark study on ARVC, aiming to develop effective treatments for this rare heart condition.

AMO Pharma Partners with PHRI and Venca Research to Conduct Groundbreaking ARVC Study #USA #London #AMO_Pharma #ARVC #PHRI